POUT: extended follow-up results скачать в хорошем качестве

POUT: extended follow-up results

Alison Birtle, MRCP, FRCR, MD, Lancashire Teaching Hospitals, Preston, UK, discusses the updated outcomes of the randomized Phase III POUT trial (NCT01993979) investigating peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). 261 patients with UTUC who had undergone nephroureterectomy were enrolled and randomized 1:1 to gemcitabine-carboplatin or surveillance. Previous follow-up at 30.3 months found that adjuvant chemotherapy improved disease-free survival (DFS) for patients with UTUC. At a median follow-up of 48.1 months this DFS benefit was maintained, with no observed detrimental long-term toxicity. Overall survival at three years was 67% for surveillance and 79% for chemotherapy, however this was not statistically significant. Dr Birtle also discusses results from the CheckMate 274 trial (NCT02632409) investigating nivolumab compared with placebo in patients with muscle invasive bladder cancer or upper urinary tract urothelial cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.